RGEN · Repligen Corporation
$131.96
+10.90% last session
End-of-day data · updated 2026-07-28
Market cap
$7B
Enterprise value
$7B
Trailing P/E
144.0
Forward P/E
51.4
Dividend yield
—
Beta
1.06
Avg volume
1M
Employees
2K
2D change
-0.68%
5D change
-4.75%
10D change
-10.99%
30D change
-10.85%
60D change
5.74%
MTD change
-5.71%
YTD change
-20.02%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — RGEN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-07
Latest call per bank · past 12 months
HSBC
Buy$150
+13.7% vs priceJP Morgan
Overweight$165
+25.0% vs priceBarclays
Overweight$160
+21.2% vs priceUBS
Buy$195
+47.8% vs priceWells Fargo
Overweight$180
+36.4% vs priceJefferies
Hold$135
+2.3% vs priceRBC Capital
Outperform$204
+54.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-07 | Benchmark | Upgrade | Hold → Buy | $0.00 → $185 |
| 2026-07-06 | Evercore ISI Group | Maintains | Outperform | $150 → $160 |
| 2026-06-03 | HSBC | Maintains | Buy | $170 → $150 |
| 2026-05-06 | JP Morgan | Maintains | Overweight | $180 → $165 |
| 2026-05-06 | Barclays | Maintains | Overweight | $145 → $160 |
| 2026-04-20 | Canaccord Genuity | Maintains | Hold | $165 → $145 |
| 2026-04-17 | Roth Capital | Initiates | Buy | $0.00 → $160 |
| 2026-04-14 | Barclays | Maintains | Overweight | $175 → $145 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-07-28
- RSI (14): RSI is 56 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 11.0% above the 50-day MA ($130.90).
- Price vs 200-day MA: Trading 3.9% above the 200-day MA ($139.94).
- MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- MACD (12,26,9): MACD histogram is negative (-1.35) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($102.87) and high ($172.26).
RGEN Price Chart
Loading chart for RGEN…
Fundamentals
About Repligen Corporation
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
More in Medical Instruments & Supplies
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.